دورية أكاديمية
mTOR Signaling Regulates Metabolic Function in Oligodendrocyte Precursor Cells and Promotes Efficient Brain Remyelination in the Cuprizone Model.
| العنوان: | mTOR Signaling Regulates Metabolic Function in Oligodendrocyte Precursor Cells and Promotes Efficient Brain Remyelination in the Cuprizone Model. |
|---|---|
| المؤلفون: | Jeffries MA; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103., McLane LE; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103., Khandker L; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103., Mather ML; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103., Evangelou AV; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103., Kantak D; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103., Bourne JN; Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado 80045., Macklin WB; Department of Cell and Developmental Biology, University of Colorado School of Medicine, Aurora, Colorado 80045., Wood TL; Department of Pharmacology, Physiology, and Neuroscience and Center for Cell Signaling, Rutgers New Jersey Medical School, Newark, New Jersey 07103 terri.wood@rutgers.edu. |
| المصدر: | The Journal of neuroscience : the official journal of the Society for Neuroscience [J Neurosci] 2021 Oct 06; Vol. 41 (40), pp. 8321-8337. Date of Electronic Publication: 2021 Aug 20. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural |
| اللغة: | English |
| بيانات الدورية: | Publisher: Society for Neuroscience Country of Publication: United States NLM ID: 8102140 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1529-2401 (Electronic) Linking ISSN: 02706474 NLM ISO Abbreviation: J Neurosci Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: Washington, DC : Society for Neuroscience Original Publication: [Baltimore, Md.] : The Society, c1981- |
| مواضيع طبية MeSH: | Brain/*metabolism , Cuprizone/*toxicity , Oligodendrocyte Precursor Cells/*metabolism , Remyelination/*physiology , TOR Serine-Threonine Kinases/*metabolism, Animals ; Brain/drug effects ; Chelating Agents/toxicity ; Male ; Mice ; Mice, 129 Strain ; Mice, Inbred C57BL ; Mice, Knockout ; Rats, Sprague-Dawley ; Remyelination/drug effects ; TOR Serine-Threonine Kinases/genetics ; Rats |
| مستخلص: | In demyelinating diseases, such as multiple sclerosis, primary loss of myelin and subsequent neuronal degeneration throughout the CNS impair patient functionality. While the importance of mechanistic target of rapamycin (mTOR) signaling during developmental myelination is known, no studies have yet directly examined the function of mTOR signaling specifically in the oligodendrocyte (OL) lineage during remyelination. Here, we conditionally deleted Mtor from adult oligodendrocyte precursor cells (OPCs) using Ng2-Cre ERT in male adult mice to test its function in new OLs responsible for remyelination. During early remyelination after cuprizone-induced demyelination, mice lacking mTOR in adult OPCs had unchanged OL numbers but thinner myelin. Myelin thickness recovered by late-stage repair, suggesting a delay in myelin production when Mtor is deleted from adult OPCs. Surprisingly, loss of mTOR in OPCs had no effect on efficiency of remyelination after lysophosphatidylcholine lesions in either the spinal cord or corpus callosum, suggesting that mTOR signaling functions specifically in a pathway dysregulated by cuprizone to promote remyelination efficiency. We further determined that cuprizone and inhibition of mTOR cooperatively compromise metabolic function in primary rat OLs undergoing differentiation. Together, our results support the conclusion that mTOR signaling in OPCs is required to overcome the metabolic dysfunction in the cuprizone-demyelinated adult brain. SIGNIFICANCE STATEMENT Impaired remyelination by oligodendrocytes contributes to the progressive pathology in multiple sclerosis, so it is critical to identify mechanisms of improving remyelination. The goal of this study was to examine mechanistic target of rapamycin (mTOR) signaling in remyelination. Here, we provide evidence that mTOR signaling promotes efficient remyelination of the brain after cuprizone-mediated demyelination but has no effect on remyelination after lysophosphatidylcholine demyelination in the spinal cord or brain. We also present novel data revealing that mTOR inhibition and cuprizone treatment additively affect the metabolic profile of differentiating oligodendrocytes, supporting a mechanism for the observed remyelination delay. These data suggest that altered metabolic function may underlie failure of remyelination in multiple sclerosis lesions and that mTOR signaling may be of therapeutic potential for promoting remyelination. (Copyright © 2021 the authors.) |
| References: | Front Mol Neurosci. 2015 Jul 27;8:35. (PMID: 26283909) J Neurosci Res. 1992 Jan;31(1):193-204. (PMID: 1613821) J Neurosci. 2010 Jun 30;30(26):8953-64. (PMID: 20592216) Glia. 2010 Nov 15;58(15):1827-37. (PMID: 20665559) Neuropathol Appl Neurobiol. 1996 Jun;22(3):199-206. (PMID: 8804021) Cell Metab. 2013 Nov 5;18(5):698-711. (PMID: 24206664) J Neurol Sci. 1987 Jun;79(1-2):141-8. (PMID: 2440995) Front Cell Dev Biol. 2018 Sep 25;6:122. (PMID: 30320109) J Neurosci. 2017 Aug 2;37(31):7534-7546. (PMID: 28694334) Am J Pathol. 2016 Mar;186(3):511-6. (PMID: 26773350) ASN Neuro. 2020 Jan-Dec;12:1759091420971916. (PMID: 33228381) J Neurol Sci. 1999 Oct 15;168(2):116-20. (PMID: 10526193) J Neurosci. 2009 May 13;29(19):6367-78. (PMID: 19439614) Neuroscientist. 2019 Aug;25(4):334-343. (PMID: 30122106) J Neurosci. 2014 Mar 26;34(13):4466-80. (PMID: 24671993) J Neurosci. 1998 Jun 15;18(12):4627-36. (PMID: 9614237) Glia. 2016 Jan;64(1):21-34. (PMID: 26352325) J Neurosci. 2014 Mar 26;34(13):4453-65. (PMID: 24671992) Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1283-94. (PMID: 20388826) PLoS One. 2017 Aug 8;12(8):e0182372. (PMID: 28792512) J Neurol Sci. 2003 Feb 15;206(2):187-91. (PMID: 12559509) Mult Scler. 2019 Mar;25(3):306-324. (PMID: 30319015) Technol Cancer Res Treat. 2018 Jan 1;17:1533033818780063. (PMID: 29916308) Glia. 2011 Nov;59(11):1754-69. (PMID: 21858874) Neuropathol Appl Neurobiol. 2011 Oct;37(6):676-84. (PMID: 21366663) J Neurosci. 2008 Jul 9;28(28):7174-83. (PMID: 18614687) Nat Neurosci. 2020 Jul;23(7):819-831. (PMID: 32424285) J Neurosci. 2014 Jun 18;34(25):8432-48. (PMID: 24948799) Neurochem Res. 2007 Feb;32(2):279-92. (PMID: 17063394) Toxicol Mech Methods. 2016 May;26(4):276-83. (PMID: 27088566) Biochemistry. 2017 Mar 14;56(10):1518-1528. (PMID: 28186720) Glia. 2020 Jun;68(6):1274-1290. (PMID: 31904150) Brain. 2008 Jul;131(Pt 7):1722-35. (PMID: 18515320) Acta Neuropathol. 2005 Jan;109(1):49-55. (PMID: 15645261) Sci Rep. 2019 Jan 22;9(1):246. (PMID: 30670706) J Cell Biol. 1980 Jun;85(3):890-902. (PMID: 6248568) Glia. 2012 Mar;60(3):476-86. (PMID: 22144101) Acta Neuropathol. 2009 Dec;118(6):723-36. (PMID: 19763593) Dev Biol. 1999 Sep 15;213(2):327-39. (PMID: 10479451) Nature. 2012 Apr 29;485(7399):517-21. (PMID: 22622581) Front Cell Neurosci. 2014 Mar 13;8:73. (PMID: 24659953) Nat Med. 2004 Jan;10(1):93-7. (PMID: 14702638) J Neurosci. 2012 Jan 4;32(1):356-71. (PMID: 22219296) Ann Neurol. 2000 Jun;47(6):707-17. (PMID: 10852536) Proc Natl Acad Sci U S A. 2009 Dec 29;106(52):22229-32. (PMID: 20080789) J Neurosci. 2000 Aug 1;20(15):5703-8. (PMID: 10908609) Neuroscience. 2019 May 15;406:667-683. (PMID: 30703503) PLoS One. 2017 Nov 21;12(11):e0188417. (PMID: 29161318) J Neurosci. 2020 Apr 8;40(15):2993-3007. (PMID: 32139584) J Neuropathol Exp Neurol. 2003 Jan;62(1):25-33. (PMID: 12528815) Nat Rev Neurosci. 2002 Sep;3(9):705-14. (PMID: 12209119) Glia. 2018 Feb;66(2):327-347. (PMID: 29068088) J Cell Biol. 2000 Mar 6;148(5):971-84. (PMID: 10704447) Front Cell Neurosci. 2014 Nov 18;8:384. (PMID: 25477781) Neurosci Biobehav Rev. 2014 Nov;47:485-505. (PMID: 25445182) Neurotox Res. 2013 Aug;24(2):244-50. (PMID: 23392957) J Neurosci. 2016 Apr 27;36(17):4698-707. (PMID: 27122029) Mt Sinai J Med. 2011 Mar-Apr;78(2):231-43. (PMID: 21425267) ASN Neuro. 2014 Sep 30;6(5):. (PMID: 25290063) Ann Neurol. 2010 Nov;68(5):703-16. (PMID: 20853437) |
| معلومات مُعتمدة: | F31 NS108521 United States NS NINDS NIH HHS; R01 NS082203 United States NS NINDS NIH HHS; R37 NS082203 United States NS NINDS NIH HHS |
| فهرسة مساهمة: | Keywords: cuprizone; glycolysis; mTOR; mitochondria; oligodendrocyte; remyelination |
| المشرفين على المادة: | 0 (Chelating Agents) 5N16U7E0AO (Cuprizone) EC 2.7.1.1 (mTOR protein, mouse) EC 2.7.11.1 (TOR Serine-Threonine Kinases) |
| تواريخ الأحداث: | Date Created: 20210821 Date Completed: 20211123 Latest Revision: 20240226 |
| رمز التحديث: | 20240226 |
| مُعرف محوري في PubMed: | PMC8496195 |
| DOI: | 10.1523/JNEUROSCI.1377-20.2021 |
| PMID: | 34417330 |
| قاعدة البيانات: | MEDLINE |
| تدمد: | 1529-2401 |
|---|---|
| DOI: | 10.1523/JNEUROSCI.1377-20.2021 |